Table 4.
Mean monthly cost estimates by histology, AJCC stage at diagnosis by treatment modality, and significant predictors of cancer‐attributable costs during the initial phasea
| N (%) | Total cost (95% CI) | Patient‐liability cost (95% CI) | Cancer‐attributable cost (95% CI) | Cancer‐attributable cost predictors | |||
|---|---|---|---|---|---|---|---|
| Year | Age | Year × age | |||||
| Adenocarcinoma | |||||||
| Stage I | 860 | ||||||
| Best supportive care | 245 (28.5) | $2958 ($2426‐$3490) | $392 ($329‐$456) | $1931 ($1366‐$2495) | |||
| Surgery | 204 (23.7) | $4054 ($2981‐$5127) | $454 ($342‐$566) | $3086 ($2014‐$4159) | |||
| Radiation | 89 (10.4) | $5712 ($4743‐$6680) | $987 ($842‐$1131) | $4506 ($3548‐$6680) | |||
| Chemoradiation | 219 (25.5) | $10 146 ($9150‐$11 142) | $1678 ($1480‐$1875) | $9021 ($8020‐$10 022) | − | ||
| Stage II | 755 | ||||||
| Best supportive care | 79 (10.5) | $2487 ($947‐$4027) | $272 ($110‐$434) | $1453 (−$5 to $2910) | − | − | + |
| Surgery | 109 (14.4) | $4564 ($2000‐$7128) | $552 ($235‐$890) | $3585 ($1027‐$6163) | |||
| Chemoradiation | 269 (36.6) | $10 781 ($9845‐$11 718) | $1614 ($1519‐$1710) | $9753 ($8813‐$10 693) | − | ||
| Surgery, chemo, and radiation | 160 (21.2) | $3925 ($3220‐$4630) | $561 ($466‐$657) | $2908 ($2188‐$3628) | |||
| Stage III | 505 | ||||||
| Best supportive care | 55 (8.4) | $1934 ($1046‐$2822) | $175 ($102‐$249) | $947 ($114‐$1780) | + | ||
| Chemoradiation | 293 (45.0) | $11 723 ($10 815‐$12 631) | $1693 ($1603‐$1873) | $10 659 ($9743‐$11 575) | − | ||
| Surgery, chemo, and radiation | 146 (22.4) | $5502 ($4014‐$6989) | $872 ($703‐$1041) | $4642 ($3177‐$6107) | |||
| Stage IV | 591 | ||||||
| Best supportive care | 47 (7.6) | $2783 ($1333‐$4233) | $371 ($188‐$554) | $1824 ($388‐$3261) | |||
| Chemotherapy | 84 (13.5) | $8076 ($6940‐$9412) | $1269 ($1096‐$1441) | $6929 ($5619‐$8239) | |||
| Chemoradiation | 420 (67.5) | $10 349 ($9668‐$11 029) | $1635 ($1544‐$1726) | $9367 ($8677‐$10 057) | |||
| Squamous cell carcinoma | |||||||
| Stage I | 384 | ||||||
| Best supportive care | 56 (13.8) | $3275 ($2298‐$4253) | $371 ($188‐$554) | $2167 ($1127‐$3207) | |||
| Radiation | 75 (18.5) | $7013 ($5796‐$8229) | $443 ($218‐$901) | $5885 ($4682‐$7089) | |||
| Chemoradiation | 206 (50.9) | $10 105 ($9306‐$10 904) | $1553 ($1450‐$1656) | $9061 ($8249‐$9873) | − | ||
| Stage II | 440 | ||||||
| Best supportive care | 45 (9.5) | $4039 ($1283‐$6795) | $376 ($177‐$576) | $2995 ($206‐$5784) | |||
| Surgery | 48 (10.1) | $5703 ($2232‐$9176) | $825 ($315‐$1334) | $4487 ($1003‐$7972) | |||
| Radiation | 58 (12.2) | $7601 ($5497‐$9706) | $1277 ($970‐$1583) | $6587 ($4457‐$8718) | |||
| Chemoradiation | 261 (54.8) | $10 671 ($9671‐$11 672) | $1633 ($1521‐$1746) | $9599 ($8589‐$10 608) | + | ||
| Stage III | 359 | ||||||
| Best supportive care | 34 (8.9) | $6026 ($1866‐$10 187) | $706 (−$81 to $1 494) | $5095 ($914‐$9277) | |||
| Radiation | 49 (12.8) | $7530 ($5655‐$9405) | $1090 ($894‐$1287) | $6172 ($4234‐$8110) | |||
| Chemoradiation | 236 (61.5) | $11 460 ($10 422‐$12 499) | $1775 ($1646‐$1905) | $10 471 ($9422‐$11 519) | |||
| Stage IV | 281 | ||||||
| Best supportive care | b | $4097 ($1539‐$6655) | $345 ($125‐$566) | $3290 ($706‐45 874) | + | + | − |
| Radiation | 36 (12.8) | $13 921 ($8725‐$19 117) | $1588 ($887‐$2288) | $12 842 ($7654‐$18 029) | |||
| Chemotherapy | 29 (10.3) | $5560 ($4074‐$7046) | $902 ($691‐$1114) | $4097 ($2517‐$5677) | |||
| Chemoradiation | 185 (65.8) | $10 125 ($9205‐$11 045) | $1543 ($1433‐$1653) | $9158 ($8236‐$10 078) | |||
Abbreviation: AJCC, American Joint Committee on Cancer; SEER, Surveillance, Epidemiology, and End Results.
A positive (+) symbol indicates that the covariate in the regression model has a parameter estimate greater than 0, while a negative (−) symbol indicates that the parameter estimate is less than 0. With the exception of best supportive care costs, treatment modality costs are not shown if less than 10% of patients within a stage/histology group received that treatment.
N suppressed in accordance with SEER‐Medicare guidelines to mask cells that may be <11 and ensure patient confidentiality.